AVIR
Atea Reports HCV Trial Positive and Receives $200M Non-Dilutive Funding
Atea announced positive HCV trial results and secured up to $200M in non-dilutive funding from Hercules Capital to advance clinical development.
AVIR news
Latest 1 stories · newest Nov 9, 2026
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same AVIR feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/AVIR/newsSTART FREE